FT-104 (also known as RE-104 and 4-glutaryloxy-N,N-diisopropyltryptamine) is a psychedelic tryptamine derivative which is a prodrug ester of the well known designer drug 4-HO-DiPT.[1] It is one of a number of related derivatives developed for potential medical applications, and is in human clinical trials as a possible treatment for postpartum depression and treatment-resistant depression.[2][3][4][5]
 | |
| Clinical data | |
|---|---|
| Other names | RE-104; RE104; 4-glutaryloxy-N,N-diisopropyltryptamine |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C21H30N2O |
| Molar mass | 326.484 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
It is being developed by the pharmaceutical company Reunion Neuroscience.[6] As of 2024, FT-104 is entering Phase II clinical trials for post-partum depression.[7]
Pharmacology
editFT-104 is a prodrug that is converted into the psychedelic tryptamine 4-HO-DiPT upon administration.[1][8] 4-OH-DiPT then acts as an agonist on the serotonin 2A receptor which leads to an antidepressant effect.[6]
See also
edit- Indopan, an antidepressant developed by the Upjohn pharmaceutical company in the 1960s.
- Monase, an antidepressant developed by the Upjohn pharmaceutical company in the 1960s.
- 4-AcO-DiPT
- 4-PrO-DMT
- THC hemisuccinate
References
edit- ^ a b Bryson N, Alexander R, Asnis-Alibozek A, Ehlers MD (June 2024). "RE104: Synthesis and Activity of a Novel Serotonergic Psychedelic Prodrug of 4-Hydroxy-N,N-diisopropyltryptamine". ACS Chemical Neuroscience. 15 (12): 2386–2395. doi:10.1021/acschemneuro.4c00058. PMC 11191588. PMID 38758589.
- ^ Hallifax J (11 August 2022). "An Inside Look into Field Trip's Next-Generation Psychedelic, FT-104".
- ^ WO 2022/000091, Bryson N, "Tryptamine prodrugs", published 6 January 2022, assigned to Field Trip Psychedelics Inc.
- ^ US 2022/0024956, Slassi A, Araujo J, "Psilocin derivatives as serotonergic psychedelic agents for the treatment of CNS disorders.", published 27 January 2022, assigned to Mindset Pharma Inc.
- ^ WO 2022/246572, Slassi A, Araujo J, Higgin GH, Gabriele J, "Hallucinogen-Fatty Acid Combination", published 1 December 2022, assigned to Mindset Pharma Inc.
- ^ a b Braner S (May 8, 2024). "Reunion Neuroscience raises $103 million for a psychedelic to treat depression". Chemical & Engineering News.
- ^ Alexander R, Hocevar-Trnka J (June 26, 2024). "RE104: A Novel, Fast-Acting Psychedelic for Postpartum Depression". psychiatrictimes.com.
- ^ "Reunion Neuroscience Announces Publication of Results from Early Preclinical Studies Demonstrating the Potential of RE104 for Development in Depressive Disorders". GlobalNewswire. May 20, 2024 – via Yahoo!Finance.